Pharmaceutical News

RSS

Researchers: Breast cancer prevention and treatment protocols not always clear

The New York Times writes about the frequent inaccuracy of a test to detect certain proteins in breast tumors, which determines whether the patient will get Herceptin, a potent breast cancer treatment. "Drugs aimed at disabling proteins that spur cancer are, many oncologists say, the future of cancer therapies.

21 Apr 2010

FDA approves Lupin Pharmaceuticals' Imipramine Pamoate capsules

Lupin Pharmaceuticals, Inc. (LPI) announced today that it has received final approval from the U.S. Food and Drug Administration (FDA) for its Imipramine Pamoate capsules, 75 mg, 100 mg, 125 mg and 150 mg strengths. Commercial shipments of the product have already commenced.

21 Apr 2010

CytRx' bafetinib receives EMEA COMP positive opinion for treatment of CML

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced that bafetinib (formerly known as INNO-406) has received official notification from the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMEA) that a positive opinion was made regarding the application for orphan medicinal product for the treatment of chronic myeloid leukemia (CML).

20 Apr 2010

Pharmacies launch Dispose My Meds campaign to help consumers safely dispose unused medications

Nearly 800 community pharmacies in 40 states are making it easier than ever for consumers to safely dispose of unused patient medications at their local pharmacy, the National Community Pharmacists Association and Sharps Compliance, Inc. announced today.

20 Apr 2010

TYSABRI drives Biogen Idec's first-quarter revenues of $1.1 billion

Biogen Idec Inc., a global biotechnology leader in the discovery, development, manufacturing, and commercialization of innovative therapies, today announced its first quarter 2010 results.

20 Apr 2010

Biovest to make presentation on BiovaxID cancer vaccine at World Vaccine Congress 2010

Biovest International, Inc. today announced that the Company will be making a presentation regarding its personalized cancer vaccine, BiovaxID, on April 22 at the World Vaccine Congress which is currently ongoing in Washington D.C.

20 Apr 2010

MicroStockProfit.com releases investment report on AEterna Zentaris

MicroStockProfit.com announces an investment report featuring AEterna Zentaris Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

20 Apr 2010

Forgetfulness, procrastination related to prescription drugs costs $163 billion in wasteful healthcare spending

Express Scripts is the first organization ever to quantify the hidden healthcare costs of very common behaviors related to prescription drugs, such as forgetfulness and procrastination, estimating the annual wasteful spending at $163 billion.

20 Apr 2010

AstraZeneca/Targacept's TC-5214 for treatment resistant depression to earn Decision Resources' gold standard status

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, for treatment resistant depression therapy, AstraZeneca/Targacept's TC-5214 will earn Decision Resources' proprietary clinical gold standard status in 2013 (following its approval that year) and through 2018.

20 Apr 2010

Low-dose aspirin associated with increased risk of gastrointestinal bleeding

Low-dose aspirin (LDA) is one of the main agents used for the prevention of thromboembolic vascular events, and has the advantages of both low cost and a prolonged duration of antiplatelet action; however, it is associated with a doubling of the risk of gastrointestinal bleeding, even at doses as low as 75 mg daily. The gender differences in the clinical manifestations of LDA-associated gastroduodenal mucosal injury have not been well studied.

20 Apr 2010

Global pharmaceutical market to reach $1.1 trillion in 2014: IMS Health

IMS Health reported today that the size of the global market for pharmaceuticals is expected to grow nearly $300 billion over the next five years, reaching $1.1 trillion in 2014. The 5 - 8 percent compound annual growth rate during this period reflects the impact of leading products losing patent protection in developed markets, as well as strong overall growth in the world's emerging countries.

20 Apr 2010

First case of treating cystic fibrosis and Crohn's disease with infliximab

Cystic fibrosis (CF) is the most common life-threatening autosomal recessive disease in Caucasian children; it has an incidence of 1 case in every 2500 children born alive. CF involves an anomalous function of the exocrine glands, caused by a mutation of a gene (cystic fibrosis transmembrane conductance regulator, CFTR) located on chromosome 7, which codes for a protein involved in ion transport through the cell membrane.

20 Apr 2010

Momenta Pharmaceuticals presents preclinical data of M402 at AACR 2010

Momenta Pharmaceuticals, Inc., a biotechnology company specializing in the characterization and engineering of complex mixture drugs, today announced presentation of results from a preclinical study of its novel oncology drug candidate, M402, in a murine pancreatic cancer model.

20 Apr 2010

FDA-approved metformin can prevent tobacco-carcinogen induced lung tumors: Study

Metformin, a mainstay of treatment for patients with type 2 diabetes, may soon play a role in lung cancer prevention if early laboratory research presented here at the AACR 101st Annual Meeting 2010 is confirmed in clinical trials.

20 Apr 2010

FDA approves Lannett's ANDA for Ondansetron Injection USP, 2 mg/mL, Multi-Dose Vials

Lannett Company, Inc. today announced that it has received approval from the U.S. Food and Drug Administration (FDA) of its Abbreviated New Drug Application (ANDA) for Ondansetron Injection USP, 2 mg/mL, Multi-Dose Vials. Ondansetron Injection USP, 2 mg/mL is the generic equivalent of GlaxoSmithKline's Zofran® Injection, 2 mg/mL. For the 12 months ending December 2009 U.S. sales of Ondansetron Injection USP, 2 mg/mL were approximately $58 million at Average Wholesale Price (AWP). A launch date for the product has not yet been set.

20 Apr 2010

Array BioPharma signs agreement with Novartis for worldwide development of ARRY-162

Array BioPharma Inc. today announced that it has entered into an agreement with Novartis for the worldwide development of the small-molecule MEK inhibitors ARRY-162, currently in a Phase 1 cancer trial, its back-up, ARRY-300, and other MEK inhibitors.

20 Apr 2010

EpiCept announces U.K. launch of Ceplene

EpiCept Corporation today announced that the commercial launch of Ceplene® (histamine dihydrochloride) will take place in the United Kingdom on April 20, 2010 in conjunction with the British Society for Haematology 50th Annual Scientific Meeting in Edinburgh, Scotland. Ceplene is approved in the European Union for the remission maintenance and prevention of relapse in patients with Acute Myeloid Leukemia (AML) in first remission.

20 Apr 2010

Higher intake of vitamin K from dietary sources associated with lower risk of Non-Hodgkin lymphoma

In the first study of vitamin K and Non-Hodgkin lymphoma risk, researchers at the Mayo Clinic campus in Minnesota have found that people who have higher intakes of vitamin K from their diet have a lower risk of developing Non-Hodgkin lymphoma.

20 Apr 2010

Novartis withdraws EMA MAA for JOULFERON

Human Genome Sciences, Inc. today announced that Novartis has withdrawn a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for approval to market JOULFERON® (albinterferon alfa-2b, known in the United States as ZALBIN™) for the treatment of chronic hepatitis C.

19 Apr 2010

Generex Biotechnology announces plan to obtain cost reimbursement coverage for Generex Oal-lyn

Generex Biotechnology Corporation, the leader in drug delivery for metabolic diseases through the inner lining of the mouth, today announced that it has established an action plan for obtaining cost reimbursement coverage for Generex Oal-lyn™, including the development of an insurance product that covers the costs of Generex Oral-lyn™ and any additional and/or comparable diabetes products.

19 Apr 2010

Pharmaceutical News

Researchers: Breast cancer prevention and treatment protocols not always clear

FDA approves Lupin Pharmaceuticals' Imipramine Pamoate capsules

CytRx' bafetinib receives EMEA COMP positive opinion for treatment of CML

Pharmacies launch Dispose My Meds campaign to help consumers safely dispose unused medications

TYSABRI drives Biogen Idec's first-quarter revenues of $1.1 billion

Biovest to make presentation on BiovaxID cancer vaccine at World Vaccine Congress 2010

MicroStockProfit.com releases investment report on AEterna Zentaris

Forgetfulness, procrastination related to prescription drugs costs $163 billion in wasteful healthcare spending

AstraZeneca/Targacept's TC-5214 for treatment resistant depression to earn Decision Resources' gold standard status

Low-dose aspirin associated with increased risk of gastrointestinal bleeding

Global pharmaceutical market to reach $1.1 trillion in 2014: IMS Health

First case of treating cystic fibrosis and Crohn's disease with infliximab

Momenta Pharmaceuticals presents preclinical data of M402 at AACR 2010

FDA-approved metformin can prevent tobacco-carcinogen induced lung tumors: Study

FDA approves Lannett's ANDA for Ondansetron Injection USP, 2 mg/mL, Multi-Dose Vials

Array BioPharma signs agreement with Novartis for worldwide development of ARRY-162

EpiCept announces U.K. launch of Ceplene

Higher intake of vitamin K from dietary sources associated with lower risk of Non-Hodgkin lymphoma

Novartis withdraws EMA MAA for JOULFERON

Generex Biotechnology announces plan to obtain cost reimbursement coverage for Generex Oal-lyn

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Latest News